Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus

Journal of Clinical Immunology

Volumn 33, Issue 2, 2013, Pages 342-348

  Wiley, Kenneth L ^a   Treadwell, Edward ^b   Manigaba, Kayihura ^a   Word, Beverly ^a   Lyn Cook, Beverly D ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

DHEA; DNA methyltransferases; DNMT1; DNMT3A; DNMT3B; Lupus

Indexed keywords

5 METHYLCYTOSINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MESSENGER RNA; PRASTERONE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DNMT1 GENE; DNMT3A GENE; DNMT3B GENE; EPIGENETICS; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SLEDI INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84879257346     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9803-z     Document Type: Article

References (46)

1. Lahita RG. Systemic lupus erythematosus. Amsterdam: Elsevier; 2004.
2. Lupus Foundation of American. Statistics about Lupus.
3. Foundation, S.L.E.L., Facts about gender and racial disparities in Lupus: Lupus targest women and minorities.
4. Ramos-Casals M, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Med (Baltimore). 2008;87(6):345-64.
5. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29 (7):707-16.
6. Calero I, Sanz I. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med. 2010;10(54):416-24.
7. Kocis P. Prasterone. Am J Health Syst Pharm. 2006;63(22):2201-10.
8. Merrill JT. Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. Expert Opin Investig Drugs. 2003;12(6):1017-25.
9. Ãstensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2000;9(8):566-72.
10. Jabin D, Kumar S, Gow PJ. Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. N Z Med J. 2010;123(1324):67-73.
11. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12(1):3.
12. Mitka M. Treatment for Lupus, first in 50 years, offers modest benefits, hope to patients. J Am Med Assoc. 2011;305(17):1754-5.
13. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40(1):66-73.
14. Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematous. Current Rheumatol Rep. 2008;10(4):286-91.
15. Luo Y, et al. Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;159(4):827-33.
16. Ballestar E, Esteller M, Richardson BC. The epigentic face of systemi lupus erythematosus. J Immunol. 2006;176:143-7.
17. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol. 1986;17:456-70.
18. Zhou Y, et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol. 2009;132(3):362-70.
19. Wei-Min S, et al. The effect of DNMTs and MBPs on hypomethylation in systemic lupus erythematosus. J Dermatol Sci. 2009;53 (3):236-8.
20. Fisher CL, Fisher AG. Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr Opin Genet Dev. 2011;21 (2):140-6.
21. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol. 2003;109(1):37-45.
22. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol. 2003;109(1):17-28.
23. Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N YAcad Sci. 2007;1108:127-36.
24. Zouali M. Epigenetics in lupus. Ann N Y Acad Sci. 2011;1217 (1):154-65.
25. Gowher H, et al. De Novo Methylation of Nucleosomal DNA by the Mammalian Dnmt1 and Dnmt3A DNA Methyltransferasesâ€. Biochemistry. 2005;44(29):9899-904.
26. Fatemi M, et al. The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J Mol Biol. 2001;309(5):1189-99.
27. Hedrich CM, Tsokos GC. Epigenetic mechanims in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714-22.
28. Hughes T, Sawalha AH. The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther. 2011;13(245):1-11.
29. Sckigawa I, Okada M, Ogasawara H, Hishikawa T, Hashimoto H. DNA methylation in systemic lupus erythematosus. Lupus. 2003;12:79-85.
30. Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmune, aging and cancer. J Nutrition. 2002;132:2401-5.
31. Zhao S, Long H, Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol. 2010;39:3-9.
32. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol. 2003;3(4):344-51.
33. Astrid S, et al. The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors. Chem Med Chem, 2009. 9999(9999): p. NA.
34. Cunliffe VT. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev. 2008;18(5):404-10.
35. Ng K, et al. Xist and the order of silencing. EMBO Rep. 2007;8(1):34-9.
36. Cheng X, Blumenthal RM. Mammalian DNA Methyltransferases: a structural perspective. Structure. 2008;16(3):341-50.
37. Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011;6:593-601.
38. Lai G, Bromberg JS. Eipigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114(18):3727-34.
39. Lu Q, Wu A, Richardson BC. Demethylaion of the same promoter sequence increaseas CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol. 2005;174(10):6212-9.
40. Lai G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182(1):259-73.
41. Liu CC, et al. Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus. 2011;20(2):131-6.
42. Zhu X, et al. Analysis of associations between the patterns of global DNA hypomethylation and expression of DNA methyltransferase in patients with systemic lupus erythematosus. Int J Dermatol. 2011;50(6):697-704.
43. Nagar M, et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25â'CD4+ T cells. Int Immunol. 2008;20(8):1041-55.
44. Makar KW, et al. Active recruitment of DNA methyltransferases regulates interleukin 4 in thymocytes and T cells. Nat Immunol. 2003;4(12):1183-90.
45. Hodge DR, et al. IL-6 Enhances the Nuclear Translocation of DNA Cytosine-5-Methyltransferase 1 (DNMT1) via Phosphorylation of the Nuclear Localization Sequence by the AKT Kinase. CANCER GENOMICS PROTEOMICS. 2007;4(6):387-98.
46. Schonthaler HB, Guinea-Viniegra J, Wagner EF. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis. 2011;70 Suppl 1:1109-12.